- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02188745
ER Reactivation Therapy for Breast Cancer (POLLY)
Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Metastatic or Advanced Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01199
- Baystate Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women ≥18 years of age with clinical stage IV ER+/HER2- breast cancer, or with locally recurrent ER+/HER2- disease not amenable to therapy for curative intent.
Patient must have been treated with an anti-estrogen at any time in their disease history. Combination regimens that include an anti-estrogen and any biologic, or targeted therapy, are permitted (e.g., any CDK inhibitor, everolimus, or any other novel biologics), and are considered to be a single hormonal therapy based regimen.
- Any number of prior lines of anti-estrogen (i.e., hormonal) therapy is permissible.
- One line of prior chemotherapy for advanced/metastatic disease is permissible.
Histologic documentation of ER strongly+/HER2- breast cancer by core needle biopsy, fine needle aspiration, incisional biopsy, or surgical biopsy of ≥1 site(s) of metastatic or locally advanced disease performed as standard of care within the past 4 months for assessment of eligibility for study participation (except as noted below in c/d/e).
- ER strongly+ status defined as ER staining by immunohistochemistry in ≥50% of malignant cell nuclei with an intensity ≥2+ on a scale of 0-3+. These criteria are equivalent to an Allred score ≥6.
- HER2-negative status is defined as immunohistochemistry score of 0-1+, or with a FISH ratio of <2 if IHC is 2+ or if IHC has not been done (as per ASCO/CAP definitions). In cases of borderline or equivocal HER2 status, eligibility will be determined by the PI.
Archived tumor specimens: Excess tumor tissue must be available for research purposes. This will include tumor tissue sufficient to make ≥10 five-micron sections; more tumor tissue is preferred.
Freshly acquired tumor specimens: As part of a clinically indicated biopsy procedure, an additional 1-3 cores or tissue fragments will be obtained by core needle or surgical biopsy for research purposes and FFPE.
- Patients with bone-only metastatic disease with a history of ER+/HER2- breast cancer are eligible, and bone biopsy is not required, providing their primary cancer is consistent with the above-described ER and HER2 criteria.
- Patients with non-bone metastatic disease in whom a safe and accurate biopsy of recurrent/metastatic disease cannot be readily obtained are also eligible, providing their primary cancer is consistent with the above-described ER and HER2 criteria.
- Patient must be a candidate for treatment with 17B-estradiol and an aromatase inhibitor.
If the most recent therapy was in the adjuvant setting, the recurrence-free interval (time from initiation of adjuvant anti-estrogen therapy to clinical evidence of disease recurrence) must have been ≥2 years.
If the most recent therapy was in the advanced/metastatic setting, the progression-free interval must have been ≥3 months (except in the case of investigational hormonal therapies).
- Patient must be post-menopausal based on either a history of an oophorectomy, or ≥1 year of amenorrhea. An elevated serum gonadotropin level and estradiol level in the postmenopausal range (as locally defined) can be used to confirm menopausal status in a subject with <1 year of amenorrhea.
- Baseline radiographic staging, including specifically either PET/CT, or CT (CAP) and bone scan.
- Patient must be capable and willing to provide informed written consent for study participation.
- The following laboratory values must be confirmed for eligibility within 28 days prior to initiation of study therapy:
Hematology panel
- hemoglobin > 9 g/dL
- white blood cell (WBC) count (≥ 2,000/uL)
- platelet count ≥ 75,000/uL Serum biochemistry/metabolic panel
- creatinine ≤ 1.5 x upper limits of normal (ULN)
- total bilirubin ≤ 1.5 x upper limits of normal (ULN)
- ALT and AST ≤ 3.0 x upper limits of normal (ULN) For patients with liver metastasis: < 5 x upper limits of normal (ULN)
Exclusion Criteria:
- Treatment with fulvestrant within 16 weeks prior to study enrollment.
Any other concurrent systemic anti-cancer treatments, including conventional chemotherapeutic agents and biological agents, during the study period.
Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.
- Any investigational cancer therapy in the last 3 weeks.
- Known CNS disease, unless clinically stable for ≥ 3 months.
History of any of the following:
- deep venous thrombosis
- pulmonary embolism
- stroke
- acute myocardial infarction
- congestive heart failure
- previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alternating Therapy
Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred. 17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day. Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day. Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day. Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day. |
Anti-estrogen
Other Names:
Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen.
This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Other Names:
Aromatase inhibitors work differently from tamoxifen and raloxifene.
Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen.
This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Other Names:
Aromatase inhibitors work differently from tamoxifen and raloxifene.
Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen.
This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit
Time Frame: 12 Months
|
Determine the rate of clinical benefit from alternating 17B-estradiol/aromatase. Clinical benefit is defined as complete response, partial response or stable disease at 24 weeks per RECIST criteria.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: 8 weeks
|
Determine the objective response rate of patients treated with 17B-estradiol therapy for 8 weeks.
Objective Response is defined as complete response + partial response as per RECIST criteria; the proportion of patients experiencing objective response on 17B-estradiol will be calculated to determine objective response rate.
|
8 weeks
|
Progression-free survival
Time Frame: 12 Months
|
Determine the progression-free survival from alternating 17B-estradiol/aromatase inhibitor therapy in patients with advanced ER+ breast cancer.
Progression-free survival is defined as the time period from the start of a treatment until the time of cancer progression or death from any cause.
Cancer progression will be determined as per RECIST criteria.
|
12 Months
|
Adverse event profiles
Time Frame: 12 Months
|
Determine the adverse event profiles of 17B-estradiol and aromatase inhibitors in this patient population.
Adverse events will be recorded as Grade 1, 2, 3, or 4. Incidences will be compared within patients over time.
|
12 Months
|
Predictive tumor genetic lesions
Time Frame: 12 Months
|
Determine whether specific tumor genetic lesions in ESR1 are predictive of response to 17B-estradiol and/or subsequent aromatase inhibitor therapies.
The rates of clinical benefit from 17B-estradiol and/or subsequent AI therapy will be compared between patients with tumors with vs. without genetic lesions in ESR1.
|
12 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mary Chamberlin, MD, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Estradiol
- Anastrozole
- Exemestane
- Aromatase Inhibitors
Other Study ID Numbers
- D14122
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on 17B-estradiol
-
National Institute on Aging (NIA)Mead Johnson NutritionCompletedAtherosclerosis | PostmenopauseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
TherapeuticsMDCompleted
-
Mary D ChamberlinDartmouth-Hitchcock Medical CenterNot yet recruitingMetastatic Breast Cancer
-
University of Southern CaliforniaNational Institute on Aging (NIA)Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVasomotor SymptomsMexico
-
Medical College of WisconsinTerminatedTransgenderism | Clotting DisorderUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedOral Contraceptive | HemostasisGermany, Israel, Italy, Spain
-
University of HelsinkiPäivikki and Sakari Sohlberg Foundation, Finland; Finnish Medical Foundation; Emil Aaltonen FoundationCompletedCardiovascular Disease | Postmenopausal Vasomotor SymptomsFinland
-
Mayo ClinicCompletedCardiovascular Risk ReductionUnited States